US govt stem cell funding "sends signal to the market"
"For an extended period of time, stem cell equities have busily conducted research under the black cloud of funding limitations," stated SmallCap Sentinel analyst D R Clark, adding: "now, with the [US] political landscape having changed so dramatically, stem cell equities are finding a more welcoming and perhaps brighter path."
A case in point is Advanced Cell Technology, which was awarded a research grant from the US National Institutes of Health in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners, Mr Clark noted: "I believe this exemplifies a dramatic change in the government's sentiment toward stem cell research while simultaneously enhancing confidence for Advanced Cell's business plan."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze